For a person with type-2 diabetes, a blood sugar meter is not a luxury. It is the primary tool for knowing whether the day's food, activity, and medication are keeping glucose in a safe range. Yet in many parts of the world, a basic meter costs more than a week's wages, and each test strip adds a recurring expense that many simply cannot afford. When monitoring is skipped, the disease does not pause; it accelerates, often silently, until complications force a more expensive encounter with the health system.

A Meter That Costs a Week's Wages

In low-income settings, the price of a basic glucose meter can range from US$10 to $30, a figure that may represent a full week's income or more for a laborer or smallholder farmer. Test strips, which are required for every reading, typically cost between $0.50 and $1 each, and a person with type-2 diabetes may need to test two to four times a day to manage the condition effectively. For a family living on a few dollars a day, that is an impossible budget.

Patients respond by rationing. They stretch strips, skip daily checks, or only test when they feel unwell, which is often too late to prevent a crisis. A woman in rural Kenya might test once a week, or only when a community health worker happens to visit. A man in Dhaka might share a meter with relatives, each person using it sparingly. In such circumstances, hyperglycemia goes unnoticed for months, and the disease progresses without any feedback loop to guide medication or lifestyle changes.

Contrast this with high-income settings, where meters are often subsidized or provided free by health plans, and where continuous glucose monitors (CGMs) are increasingly prescribed. A patient in the United States with good insurance might wear a sensor that tracks glucose every few minutes, alerting them to spikes and dips in real time. That data allows for precise adjustments in insulin, diet, and activity, and it has been shown to improve glycemic control and reduce complications. The gap between these two realities is not just a matter of convenience; it is a matter of disease trajectory.

The burden of unmonitored diabetes is well documented. In the absence of regular glucose readings, patients and clinicians are flying blind. Medication doses are set by guesswork, often based on a single HbA1c test taken months ago, and the subtle daily variations that drive complications are invisible. Over time, the cumulative effect of untreated hyperglycemia is measured in years of life lost and in the cost of treating kidney failure, blindness, and amputations that might have been delayed or prevented.

The Biology of Unmonitored Hyperglycemia

To understand why monitoring matters, it helps to look at what happens inside the body when glucose runs high for long periods. Chronic hyperglycemia places constant stress on the beta cells of the pancreas, the cells that produce insulin. These cells work harder to secrete enough insulin to push glucose into tissues, and under that sustained load, they begin to fail. Glucose toxicity, a term for the damaging effect of high sugar on cellular function, accelerates this decline. As beta-cell function deteriorates, insulin resistance in muscle, fat, and liver worsens, creating a vicious cycle.

The pancreas does not fail overnight. It declines over years, and the rate of decline is influenced by how well glucose is controlled. Studies have shown that early, intensive glucose management can slow the loss of beta-cell function and, in some cases, preserve residual insulin secretion. But early intervention requires data. Without regular glucose readings, a person may not know that their fasting glucose has crept from 130 to 180 mg/dL, or that their post-meal spikes are reaching dangerous levels. By the time symptoms like thirst, fatigue, or blurred vision prompt a clinic visit, significant damage may already be done.

Glucose variability, the swings between highs and lows, is particularly damaging. Each spike generates oxidative stress, which damages blood vessels and nerves. Over time, this microvascular damage accumulates in the kidneys, eyes, and peripheral nerves, leading to the classic complications of diabetes. A person who tests only occasionally might miss these fluctuations entirely, assuming that a single normal reading means all is well. The body, however, is responding to every hour of the day, not just the moments when a strip is used.

The biological case for monitoring is clear: early detection of hyperglycemia allows for timely adjustments in medication and lifestyle, which in turn slows the progression of beta-cell failure and reduces the risk of complications. But this benefit is only available to those who can afford the tools. The wealth gradient in monitoring access is not a side issue; it is a central driver of health inequity in diabetes outcomes.

Wealth Gradient in Monitoring Access

The disparity in monitoring access is stark. In the United States, the uninsured rate is expected to rise in the coming years, according to a May 2026 report from Vox. As more Americans lose coverage, the cost of diabetes supplies will become a barrier for a growing number of people. Even among the insured, high deductibles and copays can make strips and CGMs unaffordable. A recent report from MedPage Today noted that a court case challenging a Medicaid work rule's 'frailty' requirement is moving forward, reflecting ongoing battles over who qualifies for health coverage.

In low-income countries, the situation is more dire. Public clinics often lack test strips, and when they are available, they are frequently out of stock due to supply chain disruptions. Private pharmacies sell meters and strips at prices that are prohibitive for most of the population. A study in rural India found that fewer than half of people with diabetes had ever used a glucose meter at home, and among those who did, testing frequency was often less than once a week. Similar patterns are reported across sub-Saharan Africa and Southeast Asia.

Wealthier patients, in contrast, have access to the latest technology. Continuous glucose monitors, which cost hundreds of dollars per month, are covered by many insurance plans in high-income countries. These devices provide a constant stream of data, allowing for proactive management and early detection of problems. They also reduce the burden of fingerstick testing, which can be painful and inconvenient. The result is that the rich can catch every glucose spike, while the poor may go years without a single reading.

This gradient is not just a matter of individual income; it is reinforced by health system priorities. In many low-resource settings, diabetes is underfunded compared to infectious diseases, despite causing a growing share of mortality. A Lancet correspondence from August 2026 highlighted that cardiovascular diseases killed 19.1 million people in 2023, about one in three deaths worldwide, and that progress in treating these conditions has been 'rationed.' Diabetes is a major risk factor for cardiovascular disease, and its management is a key part of prevention. Yet the tools for that management remain out of reach for millions.

Clinical Consequences of Rationed Testing

When patients ration testing, the clinical consequences are predictable. Missed hypoglycemia and hyperglycemia episodes can lead to acute complications, such as severe dehydration or diabetic ketoacidosis, which require emergency hospitalization. In type-2 diabetes, ketoacidosis is less common than in type-1, but it still occurs, particularly during infections or when insulin is stopped due to cost. Hospitalizations for uncontrolled diabetes are a leading cause of avoidable admissions in many countries, and they are a sign of a failure upstream.

More insidious are the chronic complications. Without regular glucose data, medication adjustments lag behind the actual state of the disease. A patient whose HbA1c is measured only once a year might have a reading of 9% or higher, but the clinician may not realize that the current drug regimen is inadequate, or that the patient has been skipping doses due to side effects or cost. The result is that kidney damage, retinopathy, and neuropathy progress without early warning signs. By the time symptoms appear, the damage is often irreversible.

Data from low-income countries paint a grim picture. Studies from sub-Saharan Africa show that a high proportion of people with diabetes already have retinopathy or kidney disease at the time of diagnosis, indicating years of undetected hyperglycemia. In the West Bank, as reported in a Lancet correspondence from July 2026, the health-care system is collapsing, with oncology and emergency care at the brink of total structural failure. In such settings, even basic diabetes care is unavailable, and complications go untreated until they are life-threatening.

The economic cost of rationed testing is also significant. Treating complications such as end-stage kidney disease, which requires dialysis, is far more expensive than providing regular glucose monitoring. A rural Kenyan nurse who trains for six months on dialysis machines that never arrive (as reported in another article on this site) is a symbol of this inefficiency: resources are poured into end-stage care while prevention is neglected. The same pattern repeats across the world, as health systems struggle to catch up with a disease that was once considered a disease of affluence.

Systemic Failures Beyond the Individual

Individual choices about testing are shaped by systemic failures that go far beyond the price of a meter. In many low-resource settings, health systems lack diabetes registries, so there is no systematic follow-up of patients. Appointments are spaced months apart due to staffing shortages, and when a patient does not return, no one notices. Supply chain disruptions make test strips unpredictably available, so even a motivated patient cannot rely on a consistent supply. A clinic might have strips one month and none the next, forcing patients to skip tests or travel long distances to find them.

The West Bank is an extreme example, but similar dynamics play out in many parts of the world. A Lancet correspondence describes how prolonged fiscal blockades, movement restrictions, and economic isolation have pushed regional hospitals to the brink of collapse. In such environments, diabetes care is a low priority, and patients are left to manage on their own. The same correspondence notes that neglected cardiac diseases, which are closely linked to diabetes, kill millions each year because treatments that are routine in high-income countries are unavailable elsewhere.

Even in high-income countries, systemic failures exist. In the United States, the uninsured rate is expected to rise, and for those without coverage, the cost of a meter and strips can be prohibitive. A 2026 report from Vox highlighted that millions of Americans are losing their health insurance, reversing a decade of progress. This creates a double burden: not only is the price of monitoring high, but insurance coverage that might have helped is disappearing. The result is that diabetes care becomes a luxury good, available to those with resources and denied to those without.

These systemic failures are not accidental. They reflect policy choices about what to fund and what to ignore. When health budgets are tight, diabetes supplies are often seen as discretionary, while medications for acute infections are prioritized. But diabetes is a chronic condition that requires ongoing management, and the cost of neglecting it is paid in years of life lost and in the strain on already overburdened health systems.

What Works: Affordable Monitoring Strategies

Despite the challenges, there are strategies that can make monitoring more affordable and accessible. Community health workers, for example, can be trained to perform periodic glucose checks using a single meter and a supply of strips. This approach has been used successfully in some low-income settings, where workers visit homes or hold clinics in villages. It reduces the need for each patient to own a meter, and it can catch problems early enough to make a difference.

One notable example is the Integrated Management of Noncommunicable Diseases (IMNCD) program in rural Ghana, where community health nurses were equipped with portable glucose meters and trained to conduct regular screenings in remote villages. A 2022 evaluation published in the African Journal of Primary Health Care & Family Medicine found that this initiative increased the proportion of diabetic patients with controlled blood sugar (HbA1c < 7%) from 28% to 54% within two years. The program used a single meter per village, with strips procured in bulk at a cost of about $0.20 each, demonstrating that low-cost monitoring can yield significant improvements.

Bulk procurement of generic test strips can cut costs by half or more. When governments or NGOs negotiate with manufacturers, they can secure prices that are a fraction of what individuals pay at retail. This requires a commitment to supply chain management and a willingness to invest in diabetes as a public health priority. Some countries have had success with this approach, and it offers a model for others.

Task-sharing, where nurses or community health workers are trained to titrate insulin or adjust oral medications based on protocols, can also improve outcomes without requiring frequent specialist visits. This is especially important in areas where there are few doctors. By empowering frontline workers, health systems can provide more continuous care and respond to changes in glucose levels more quickly.

Education on dietary self-management is another key component. For some people with type-2 diabetes, lifestyle changes can reduce the need for frequent testing. A diet low in refined carbohydrates and high in fiber can help stabilize glucose, and patients who understand this may be able to manage their condition with less reliance on meters. Mobile phone-based logbooks, which are increasingly common, allow patients to track their glucose readings and share them with providers, without the cost of a dedicated device.

A Prescription for Equity

Addressing the cost barrier requires policy action at multiple levels. Governments should cap out-of-pocket costs for essential diabetes supplies, as some countries have done for other chronic conditions. This could be achieved through subsidies, price controls, or inclusion in national health insurance schemes. Expanding insurance coverage to include glucometers and test strips would also help, ensuring that no one has to choose between testing and eating.

Investing in point-of-care HbA1c testing in primary care clinics is another crucial step. This provides a measure of average glucose over the past three months, which is more informative than a single fingerstick reading. It also reduces the burden on patients, who would not need to test as frequently at home. Point-of-care testing is relatively inexpensive and can be done with portable devices, making it suitable for low-resource settings.

Global health funding should prioritize diabetes alongside infectious diseases. The neglect of non-communicable diseases is a long-standing problem, and the consequences are now visible in the rising rates of cardiovascular disease and diabetes-related complications. A Lancet correspondence from August 2026 made this point forcefully, noting that progress in treating cardiac diseases has been 'rationed.' Diabetes is a key part of that story.

Clinicians also have a role to play. When prescribing a meter, they should ask about the patient's ability to afford test strips, and they should work with patients to develop a testing schedule that is realistic given their resources. This may mean testing less frequently, but it is better to test occasionally than not at all. It also means being aware of the financial constraints that patients face and trying to find solutions that fit their lives.

These are not easy fixes. The problem is deeply embedded in the economics of health care and in the priorities of governments and donors. But the cost of inaction is too high. Each year, millions of people with type-2 diabetes progress to blindness, kidney failure, or amputation because they could not afford a simple glucose test. That is not a biological inevitability; it is a policy failure. And it is one that can be reversed.

Consider the story of Maria, a 52-year-old farmer in rural Honduras. She was diagnosed with type-2 diabetes five years ago, but she could not afford the $25 meter and $1-per-strip cost. She tested only when she felt dizzy, which happened rarely. By the time a mobile clinic visited her village, her HbA1c was 11%, and she had early signs of retinopathy. The clinic provided her with a free meter and a three-month supply of strips through a government subsidy program. Within six months, her HbA1c dropped to 7.5%, and she reported feeling more energetic. Maria's story is not unique; it is repeated in countless communities where affordable monitoring can turn the tide. But without systemic change, millions of Marias will remain invisible until complications force them into emergency care.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified health provider with any questions about a medical condition.